DEF 14A: Bowen Acquisition Seeks Extension for Qianzhi Merger

Bowen Acquisition Corp. seeks shareholder approval to extend its business combination deadline to June 14, 2026, to finalize its merger with Shenzhen Qianzhi BioTechnology Co. Ltd.

Summary

• An Extraordinary General Meeting will be held virtually on December 12, 2025, at 10:00 a.m. Eastern Time.
• Shareholders will vote on an Extension Proposal to amend the company's articles of association, allowing the Board to extend the business combination deadline by up to six one-month increments, from December 14, 2025, to as late as June 14, 2026.
• Shareholders will also vote on an Adjournment Proposal, if necessary, to allow the Board to adjourn the Extraordinary General Meeting to a later date to consummate the Extension.
• The company previously entered into a definitive agreement for its initial business combination with Shenzhen Qianzhi BioTechnology Co. Ltd. (Qianzhi), which shareholders approved in January 2025, but the transaction has not yet been consummated.
• Without the Extension, the company would be required to cease operations, liquidate, and dissolve if the business combination is not completed by December 14, 2025.
• Public Shareholders have the option to redeem their Public Shares for cash, anticipated to be approximately $11.35 per share, based on the Trust Account balance of approximately $8.26 million as of November 20, 2025.
• The deadline to request redemption in connection with the Qianzhi business combination has passed; if the Extension is implemented and public shareholders do not redeem now, they will not have another redemption right if the proposed business combination is completed.
• The company's Sponsors, officers, and directors beneficially own an aggregate of 2,066,782 ordinary shares, representing approximately 69% of outstanding shares, and intend to vote in favor of the Extension Proposal, making its approval highly likely.

Sentiment

Score: 3

Explanation: The company is in a highly precarious position, facing repeated delays in its core business objective (merger completion), a Nasdaq delisting threat with trading halted, and significant shareholder redemptions. While the extension offers a lifeline, the accumulation of adverse events indicates substantial operational and regulatory challenges, making the outlook negative despite management's efforts to proceed.

Positives

• The Board believes the Extension Proposal is advisable and in the best interest of the Company and its shareholders to allow more time to complete the business combination with Qianzhi.
• Public shareholders are being offered redemption rights at an anticipated per-share price of approximately $11.35, which is above the initial IPO price of $10.00.
• The significant ownership stake (approximately 69%) and stated intent of Sponsors, officers, and directors to vote FOR the Extension Proposal make its approval highly probable, preventing immediate liquidation due to the current deadline.

Negatives

• The company has failed to consummate its business combination with Qianzhi by the original and previously extended deadlines, necessitating this further extension.
• There is a risk of liquidation and dissolution if the Extension Proposal is not approved or if the business combination is not completed by the new extended date.
• The company received a Nasdaq delisting determination letter on July 15, 2025, and trading in its securities was halted due to non-compliance with multiple listing rules and failure to meet a conditional deadline for the business combination.
• Withdrawals from the Trust Account due to redemptions will reduce available funds, potentially requiring additional financing that may not be available on acceptable terms or at all.
• The company faces a risk of being deemed an unregistered investment company under the Investment Company Act, which could force liquidation.
• Conflicts of interest exist for Sponsors, directors, and officers, whose Founder Shares and Private Shares would become worthless upon liquidation, potentially influencing their voting decisions.

Risks

• **Potential Application of the Investment Company Act**: The company may be deemed an unregistered investment company due to the prolonged search for a business combination and investment of IPO funds, which could lead to liquidation.
• **Nasdaq Listing**: The company is at risk of delisting from Nasdaq due to non-compliance with listing rules (minimum 400 total shareholders, $50M Market Value of Listed Securities, 1.1M Publicly Held Shares, $15M Market Value of Publicly Held Shares) and failure to complete its business combination by a conditional deadline. Nasdaq has already determined to delist, and an appeal is pending, making it significantly more difficult to consummate a business combination.
• **Committee on Foreign Investment in the United States (CFIUS)**: The proposed business combination may be subject to U.S. foreign investment regulations and review by CFIUS due to the significant ties of the company's Chairwoman, a director, and most executive officers to China, potentially blocking or delaying the transaction or imposing conditions.
• **Qianzhi Business Combination**: There are inherent risks and uncertainties associated with the proposed business combination with Qianzhi, as detailed in the related proxy statement.
• **Conflicts of Interest**: The company's Sponsors, directors, and officers have interests (e.g., ownership of Founder Shares and Private Shares) that may differ from public shareholders, as their investments would be worthless upon liquidation.
• **Liquidation Risk**: If the Extension Proposal is not approved or if the business combination is not completed by the Extended Date, the company will liquidate, extinguishing Public Shareholders' rights and rendering Founder Shares and Private Shares worthless.
• **Reduced Trust Account Funds**: Redemptions will decrease the amount in the Trust Account, potentially necessitating additional funds for a business combination, which may not be available.
• **Passive Foreign Investment Company (PFIC) Rules**: The company is likely a PFIC for U.S. tax purposes, which can result in adverse tax consequences for U.S. Holders.
• **Creditor Claims**: There is no assurance that the per-share distribution from the Trust Account, in the event of liquidation, will not be reduced due to unforeseen claims of creditors.

Future Outlook

The company intends to continue its efforts to complete the initial business combination with Qianzhi until the Extended Date of June 14, 2026, if the Extension Proposal is approved. However, there is no assurance that additional funds, if needed due to redemptions, will be available on acceptable terms or at all, nor can the company assure that the business combination will ultimately close.

Management Comments

• "Our Board believes that it is advisable and in our best interest of the Company and our shareholders to obtain the Extension in case it becomes necessary to consummate our initial business combination."
• "We are not asking you to vote on our business combination at this time."
• "Our Board unanimously recommends that our shareholders vote FOR the approval of the Extension Proposal."
• "If presented, our Board unanimously recommends that our shareholders vote FOR the approval of the Adjournment Proposal."

Industry Context

This filing reflects a common challenge for Special Purpose Acquisition Companies (SPACs) nearing their dissolution deadline without completing a de-SPAC transaction. The need for multiple extensions, significant shareholder redemptions, and a Nasdaq delisting threat are indicative of the difficulties many SPACs face in identifying and closing suitable business combinations, especially in a complex regulatory environment involving international targets and potential CFIUS review. The situation highlights the increased scrutiny and market skepticism towards SPACs that fail to execute their initial purpose efficiently.

Comparison to Industry Standards

• The company's repeated need for extensions to complete its business combination, despite prior shareholder approval, is worse than the industry standard for successful SPACs, which typically close within their initial or first extended timeframe.
• The significant volume of Public Share redemptions in prior extension votes (e.g., over 6 million shares in January 2025) is substantially higher than average for successful SPACs, indicating a lack of confidence from public shareholders in the proposed merger or the company's prospects.
• The receipt of a Nasdaq delisting determination letter and the halt of trading are severe adverse events, significantly worse than industry standards for publicly traded companies, reflecting a failure to maintain basic listing compliance.
• The anticipated per-share redemption price of approximately $11.35 is favorable for redeeming public shareholders, as it represents a premium over the initial $10.00 IPO price, which is a standard protective feature of SPACs.

Corporate Governance

Legal Proceedings

• **Nasdaq Delisting Proceedings**: The company received a delisting determination letter from Nasdaq on July 15, 2025, and its securities were halted from trading. Following an appeal and a conditional listing grant, Nasdaq issued another delisting decision on October 30, 2025, due to the company's failure to meet the October 15, 2025, deadline for its business combination. The company has requested a review of this decision by the Nasdaq Listing and Hearing Review Council.
• **Potential Investment Company Act Claims**: There is a risk that a claim could be made that the company has been operating as an unregistered investment company, which could lead to liquidation.

Related Party Transactions

• Sponsors (Createcharm Holdings Ltd and Bowen Holding LP) and EarlyBirdCapital acquired Founder Shares and Private Placement Units at a significantly lower cost than the IPO price.
• Sponsors, officers, and directors have interests in the proposals that may be different from public shareholders, including the value of their Founder Shares and Private Shares, which would be worthless upon liquidation.
• Qianzhi and EarlyBirdCapital loaned the company an aggregate of $690,000, evidenced by promissory notes, to extend the business combination deadline.

Stakeholder Impact

• **Shareholders**: Public shareholders must decide whether to redeem their shares for cash at an anticipated premium or hold them, risking further delays, potential delisting, and eventual liquidation if the business combination fails. Founder and Private shareholders face the risk of their investments becoming worthless if the company liquidates.
• **Management/Board**: Their continued roles and the value of their significant equity holdings (Founder and Private Shares) are directly tied to the approval of the extension and the successful completion of the business combination.
• **Qianzhi BioTechnology Co. Ltd.**: The target company's merger is contingent on Bowen Acquisition Corp. securing the extension and resolving its listing and operational challenges.
• **Creditors**: In the event of liquidation, the company is obligated under Cayman Islands law to provide for claims of creditors, which could potentially reduce the per-share distribution from the Trust Account to shareholders.

Next Steps

• Shareholders will vote on the Extension Proposal and Adjournment Proposal at the Extraordinary General Meeting on December 12, 2025.
• If the Extension Proposal is approved, the Board will have the discretion to extend the business combination deadline up to June 14, 2026.
• The company will continue its efforts to complete the business combination with Shenzhen Qianzhi BioTechnology Co. Ltd.
• Public shareholders must elect to redeem their shares by 5:00 p.m. Eastern Time on December 10, 2025, if they wish to do so.
• The company has requested a review of Nasdaq's delisting decision by the Nasdaq Listing and Hearing Review Council.

Key Dates

Recommendation

The company is in a highly distressed state, evidenced by repeated failures to close its business combination, a Nasdaq delisting notice, and a trading halt. While the extension offers a slim chance to complete the merger, the accumulation of severe operational, regulatory, and market challenges creates an exceptionally high-risk environment. Public shareholders have a current opportunity to redeem their shares at a premium to the IPO price, which represents a prudent exit strategy to avoid further potential capital loss and prolonged uncertainty associated with the company's precarious future.

Keywords

SPAC, business combination, extension, liquidation, redemption, Qianzhi, Nasdaq, delisting, CFIUS, proxy statement, corporate governance, blank check company, merger, China